![](/wp-content/uploads/2018/10/MBqrEZ1tTXuvq4EaPRhp.png)
$599
Novo’s Oral Sema Alzheimer’s Studies Posted on CT.gov; Saxenda Receives Positive CHMP Opinion
Two cardiometabolic-related news items have been observed: the CT.gov records for Novo’s oral semaglutide Ph3 Alzheimer’s disease trials have been posted and Novo Nordisk announced Saxenda received a positive CHMP opinion for the treatment of obesity in adolescents. Below, FENIX provides highlights and insights for the respective items.